- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- F-10 Registration of securities (Canada)
- 3.1 Articles of Angiotech Pharmaceuticals, Inc.
- 3.2 Articles of 0741693 B.C. LTD.
- 3.3 Articles of 0761717 B.C. LTD.
- 3.4 Memorandum and Articles of Association
- 3.5 Memorandum and Articles of Association
- 3.6 Memorandum and Articles of Association
- 3.7 Memorandum and Articles of Association
- 3.8 Memorandum and Articles of Association
- 3.9 Memorandum and Articles of Association
- 3.10 Memorandum and Articles of Association
- 3.11 Memorandum and Articles of Association
- 3.12 Memorandum and Articles of Association
- 3.13 Memorandum and Articles of Association
- 3.14 Memorandum and Articles of Association
- 3.15 Order of Amalgamation
- 3.16 Partnership Agreement
- 3.17 Order of Amalgamation
- 3.18 Certificate of Merger of Afmedica, Inc.
- 3.19 Bylaws of Afmedica, Inc.
- 3.20 Certificate of Incorporation
- 3.21 Amended and Restated Bylaws
- 3.22 Certificate of Incorporation
- 3.23 Bylaws of American Medical Instruments, Inc.
- 3.24 Certificate of Incorporation
- 3.25 Bylaws of Angiotech Biocoatings Corp.
- 3.26 Articles of Organization
- 3.27 Operating Agreement
- 3.28 Amended and Restated Articles of Incorporation
- 3.29 Bylaws of Angiotech Pharmaceuticals (Us), Inc.
- 3.30 Certificate of Incorporation
- 3.31 Bylaws of B.G. Sulzle, Inc.
- 3.32 Articles of Organization
- 3.33 Operating Agreement
- 3.34 Certificate of Incorporation
- 3.35 Bylaws of Manan Medical Products, Inc.
- 3.36 Certificate of Incorporation
- 3.37 Bylaws of Medical Device Technologies, Inc.
- 3.38 Certificate of Merger
- 3.39 Bylaws of of Neucoll, Inc.
- 3.40 Articles of Incorporation
- 3.41 Bylaws of Point Technologies, Inc.
- 3.42 Certificate of Incorporation
- 3.43 Bylaws of Surgical Specialties Corporation
- 3.44 Certificate of Incorporation
- 3.45 Bylaws of Quill Medical, Inc.
- 3.46 Certificate of Incorporation
- 3.47 Amended and Restated Bylaws
- 3.48 Memorandum and Amended Articles of Association
- 3.49 Memorandum & Articles of Association
- 3.50 Memorandum & Articles of Association
- 4.1 Indenture
- 4.2 Supplemental Indenture
- 5.1 Opinion of Sullivan & Cromwell LLP, Special Us Counsel
- 5.2 Opinion of Irwin, White & Jennings, British Columbia Counsel
- 5.3 Opinion of Stewart Mckelvey, Nova Scotia Counsel
- 5.4 Opinion of Lionel Sawyer & Collins, Nevada Counsel
- 5.5 Opinion of Heller Ehrman White & Mcauliffe LLP, Washington Counsel
- 5.6 Opinion of Faegre & Benson LLP, Colorado Counsel
- 5.7 Opinion of Mcconnell Valdes, Puerto Rico Counsel
- 5.8 Opinion of Herbert Smith LLP, England & Wales
- 23.1 Consent of Ernst & Young LLP
- 23.2 Consent of Pricewaterhousecoopers LLP
- 23.3 Consent of Hughes Pittman and Gupton LLP
- 25.1 Statement of Eligibility of the Trustee on Form T-1
- 99.1 Letter of Transmittal
- 99.2 Notice of Guaranteed Delivery
Exhibit 23.1
[LETTERHEAD OF ERNST & YOUNG LLP]
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Independent Accountants” in the Registration Statement (Forms F-10, F-4 and S-4) and related Prospectus of Angiotech Pharmaceuticals, Inc. for the registration of US$250,000,000 7.75% Senior Subordinated Notes due 2014, and to the incorporation by reference therein of our report dated February 10, 2006, except as to note 17b(iii) as to which the date is February 24, 2006, with respect to the consolidated financial statements of Angiotech Pharmaceuticals, Inc., and our report dated February 10, 2006 with respect to Angiotech Pharmaceuticals, Inc. management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Angiotech Pharmaceuticals, Inc., included in Exhibit 2 of its Annual Report (Form 40-F) for the year ended December 31, 2005, filed with the Securities and Exchange Commission and our report dated February 10, 2006, except as to note 17b(iii) as to which the date is February 24, 2006 and note 22 as to which the date is September 13, 2006, with respect to the consolidated financial statements of Angiotech Pharmaceuticals, Inc. included in its Report of Foreign Private Issuer (Form 6-K) for the year ended December 31, 2005, furnished to the Securities and Exchange Commission.
Vancouver, Canada | /s/ Ernst & Young LLP | |
October 24, 2006 | Chartered Accountants |